A phase II study of a PPARγ agonist TZD, troglitazone, was carried out in metastatic breast cancer patients who displayed few clinical benefits, as the advanced stage of disease resulted in a breast cancer refractory to cytotoxic therapy [44]. The gene discussed is PPARG; the disease is breast cancer.